文献速递心律失常心力衰竭与心肌病

心肌病单形性室速患者在ICD植入时行一线导管消融:PAUSE-SCD随机试验

First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial.
PubMed 文献 · Circulation · 2022-05-04

PAUSE-SCD为国际多中心随机对照试验,纳入121例心肌病合并单形性室速且符合ICD植入指征的患者,1:1随机至消融+ICD组或常规药物+ICD组。中位随访31个月,消融组主要复合终点(室速复发、心血管住院或死亡)发生率为49.3%,对照组为65.5%(HR 0.58,95%CI 0.35-0.96;P=0.04),差异主要由室速复发减少驱动。

要点

  • 心肌病单形性室速患者在ICD植入时行早期导管消融,可降低室速复发、心血管住院或死亡的复合终点。
  • 消融组ICD电击(10.0% vs 24.6%;P=0.03)和抗心动过速起搏(16.2% vs 32.8%;P=0.04)均显著减少。
  • 心血管住院和死亡率两组无显著差异,消融相关并发症发生率为8.3%。

核心结论

  • 在病因多样的心肌病患者中,ICD植入时行早期导管消融显著降低室速复发、心血管住院或死亡的复合主要终点,该获益由ICD治疗减少驱动。

研究设计与样本

  • 国际多中心随机对照试验纳入180例心肌病合并单形性室速且符合ICD植入指征的患者,其中121例随机(1:1)至消融+ICD组或常规药物+ICD组;拒绝ICD的47例进入前瞻性注册研究接受单独消融。

主要发现

  • 随机患者平均年龄55岁(四分位距46-64),左室射血分数40%(四分位距30%-49%),男性占81%。
  • 基础心脏病为缺血性心肌病35%、非缺血性心肌病30%、致心律失常性心肌病35%。
  • 消融中位在ICD植入前2天进行(四分位距植入前5天至植入后14天)。
  • 31个月时主要终点在消融组发生49.3%、对照组65.5%(HR 0.58,95%CI 0.35-0.96;P=0.04),差异由室速复发减少驱动(HR 0.51,95%CI 0.29-0.90;P=0.02)。
  • 消融组ICD电击(10.0% vs 24.6%;P=0.03)和抗心动过速起搏(16.2% vs 32.8%;P=0.04)均显著低于对照组;心血管住院(32.0% vs 33.7%;HR 0.82,95%CI 0.43-1.56;P=0.55)和死亡(8.9% vs 8.8%;HR 1.40,95%CI 0.38-5.22;P=0.62)无显著差异;消融相关并发症发生率为8.3%。

临床怎么用

  • 对于心肌病合并单形性室速且计划植入ICD的患者,可考虑在ICD植入时行早期一线导管消融以减少室速复发和ICD治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Catheter ablation as first-line therapy for ventricular tachycardia (VT) at the time of implantable cardioverter defibrillator (ICD) implantation has not been adopted into clinical guidelines. Also, there is an unmet clinical need to prospectively examine the role of VT ablation in patients with nonischemic cardiomyopathy, an increasingly prevalent population that is referred for advanced therapies globally. METHODS: We conducted an international, multicenter, randomized controlled trial enrolling 180 patients with cardiomyopathy and monomorphic VT with an indication for ICD implantation to assess the role of early, first-line ablation therapy. A total of 121 patients were randomly assigned (1:1) to ablation plus an ICD versus conventional medical therapy plus an ICD. Patients who refused ICD (n=47) were followed in a prospective registry after stand-alone ablation treatment. The primary outcome was a composite end point of VT recurrence, cardiovascular hospitalization, or death. RESULTS: Randomly assigned patients had a mean age of 55 years (interquartile range, 46-64) and left ventricular ejection fraction of 40% (interquartile range, 30%-49%); 81% were male. The underlying heart disease was ischemic cardiomyopathy in 35%, nonischemic cardiomyopathy in 30%, and arrhythmogenic cardiomyopathy in 35%. Ablation was performed a median of 2 days before ICD implantation (interquartile range, 5 days before to 14 days after). At 31 months, the primary outcome occurred in 49.3% of the ablation group and 65.5% in the control group (hazard ratio, 0.58 [95% CI, 0.35-0.96]; P=0.04). The observed difference was driven by a reduction in VT recurrence in the ablation arm (hazard ratio, 0.51 [95%CI, 0.29-0.90]; P=0.02). A statistically significant reduction in both ICD shocks (10.0% versus 24.6%; P=0.03) and antitachycardia pacing (16.2% versus 32.8%; P=0.04) was observed in patients who underwent ablation compared with control. No differences in cardiovascular hospitalization (32.0% versus. 33.7%; hazard ratio, 0.82 [95% CI, 0.43-1.56]; P=0.55) or mortality (8.9% versus 8.8%; hazard ratio, 1.40 [95% CI, 0.38-5.22]; P=0.62]) were observed. Ablation-related complications occurred in 8.3% of patients. CONCLUSIONS: Among patients with cardiomyopathy of varied causes, early catheter ablation performed at the time of ICD implantation significantly reduced the composite primary outcome of VT recurrence, cardiovascular hospitalization, or death. These findings were driven by a reduction in ICD therapies. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02848781.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Tung R, Xue Y, Chen M, et al. First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial. Circulation. 2022. PMID: 35507499. doi:10.1161/CIRCULATIONAHA.122.060039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。